The idea of getting patents is a good moves from the point of view of enforcing the patent rights. Let’s talk about haptic technology patented by Immersion.U.S. Patent No. 8,619,051 titled ‘Haptic Feedback System and Stored Effects‘ which deploys feedback to a device by responding with a vibration and the ability to store the feedback patterns and effects.
Important International Patent Classifications Identified by the Patent Examiner in this Patented Innovation:
G06F3/041Digitisers, e.g. for touch screens or touch pads, characterised by the transducing means
G06F3/016Input arrangements with force or tactile feedback as computer generated output to the user
H04M19/04Current supply arrangements for telephone systems providing ringing current or supervisory tones, e.g. dialling tone, busy tone ringing-current generated at substation
H04M19/048Arrangements providing optical indication of the incoming call, e.g. flasher circuits
Haptic devices incorporate microcontrollers, drivers, actuators or motors, as well as software for multimodal experiences that improve the usability by engaging touch, sound and sight. Haptics is widely becoming a tool used in a variety of applications they can be found in virtual reality applications to give a greater sense of realism or create a 3D environment. The haptic technology has been found in smartphones and computer and video games for many years but the innovations utilizing haptic technology is now integrating haptic technology into healthcare, transportation, robotics etc.
Some of the recent patents based on haptic technology:
Title: Eye tracking to move the cursor within view of a pilot
Assignee: Rockwell Collins, Inc. (Cedar Rapids, IA, US)
Publication Date: 28 Nov 2017
The present disclosure is directed to a method for managing a location of a cursor on a display. The method may include the step of receiving an input from a user. The method may also include the step of detecting a gaze of the user within the display. The method may also include the step of displaying the cursor on the display within the gaze of the user.
Title: NOVEL PORTABLE DEVICE HAVING A CHANGEABLE ILLUMINATED DISPLAY AND COMMUNICATIONS PLATFORM
Assignee: Eiland, Donald Curtis (Milpitas, CA, US)
Publication Date: 7 Dec 2017
The present invention relates generally to illuminated display devices and methods of displaying indicia, advertisements, etc. on a changeable illuminated display. The display device comprises a frame structure, a plurality of openings formed in the frame structure, the plurality of openings comprising first and second open spaces disposed at top and bottom positions, respectively, of the frame structure, and the plurality of openings further comprising a third open space disposed between the first and second open spaces. The display device further comprises a compact image display device operable to display an image, the compact image display device held and positioned relative to the frame structure such that first, second, and third different portions of the image, when displayed by the compact image display device, are visible through the plurality of openings first, second, and third open spaces, respectively. Additionally, control circuitry is coupled to the compact image display device.
Title: Haptic augmented and virtual reality system for simulation of surgical procedures
Assignee: IMMERSIVE TOUCH, INC. (Westmont, IL, US)
Publication Date: 7 Feb 2017
The present technology relates to systems, methods and devices for haptically-enabled virtual reality simulation of cerebral aneurysm clipping, wherein a user uses two physical stations during the simulation. The first station is a haptic and augmented reality station, and the second station is a haptic and virtual reality station.
The first thought that comes to creative intellectual mind in Industry 4 Era is Internet and combination with so many souls in the online world. What is Software? What is Software-Hardware Product? How to deploy Software-Hardware Patents?
“Jaan hai to Jahan Hai”. (If) there’s life, then there’s the world.
If there’s anything worth using technology, it’s for keeping ourselves alive and healthy. With the development in technology, healthcare in India is showing a gradual progress. The medical industry has undoubtedly benefited hugely from technological advancements and is the most promising market for businesses across the globe. There are millions of opportunities to create an evolving business by tackling the major medical challenges of the mass population. Numerous startups and companies are looking to HealthTech to offer life-changing products that harness innovation to enhance quality of care. But what are the latest developments in the works, and which companies are fuelling them?
1). Scalp cooling to prevent chemotherapy-related hair loss
Chemotherapy-induced temporary hair loss is one of the most common and distressing side-effects of cancer therapy. The Scalp cooling system has the potential to reduce cellular uptake of chemotherapy agents and decrease the chances of hair follicles experiencing damage from chemotherapy. During the clinical trial, 50.5% of patients were able to preserve their hair using the scalp cooling system. The system was FDA-approved in May 2017 and is starting to become available in hospitals nationwide.
Title: Head cooler
Assignee: Dignitana AB
Publication Date: 11 Aug 2015
Abstract: A head cooler (10) comprises a thermal exchange cap (11) and an outer insulating cover (12) to be arranged on a patient’s head. The cap (11) has a channel system (31, 32) for a cooling fluid forming an inside heat exchange surface to be applied on said head for cooling the head. The thermal exchange cap (11, 60) is adjustable and/or adaptable to compensate for a discrepancy in shape and size between the inside surface of the head cooler (10) and the head. The head cooler (10) may further comprise an eyebrow cooler (140) for cooling the area of the eyebrows. The head cooler (140) is used in medicine. A method for preventing hair loss of a patient is provided by arranging the head cooler (10) on the head of said patient.
2. Centralized medical monitoring system
In a hospital health care monitoring system it is necessary to constantly monitor the patient’s physiological parameters
Title: Medical monitoring system based on sound analysis in a medical environment
Assignee: KONINKLIJKE PHILIPS N.V.
Publication Date: 23 May 2017
Abstract: The invention relates to a medical monitoring system (100) based on sound analysis in a medical environment. A sound level analyzer (SLA, 10) is capable of providing an indicator for perceived levels of sound from a number of sound events, and a data storage modality (DSM, 20) is receiving and storing said indicator for perceived levels of sound and also corresponding information from an associated patient monitoring system (PMS, 60) handling information indicative of a physical and/or mental condition of a patient under influence by sound. A sound event analyzer (SEA, 30) is further being arranged for performing, within a defined time window, an overall sound analysis (ANA, 50) related to physical and/or mental condition of the patient that may be influenced by sound in order to assist or supervise medical personal with respect to the acoustic environment.
3. Enhanced recovery after surgery
Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery.
Title: Compositions and methods for enhancing recovery after surgery or an athletic performance
Assignee: Top Doctors Labs (Fairfield, CA, US)
Publication Date: 15 March 2016
Abstract: The invention provides compositions and dosage forms, e.g., in the form of dietary supplements, such as pills, tablets, beverages, or gels, that enhance recovery after surgery or after an athletic performance. An exemplary composition or dosage form comprises about 5000 IU of vitamin A, about 15 mg of vitamin B1, about 34 mg of vitamin B2, about 25 mg of vitamin B3, about 50 mg of vitamin B5, about 20 mg of vitamin B6, about 90 μg of vitamin B12, about 300 mg of vitamin C, about 500 IU of vitamin D, about 60 IU of vitamin E, about 160 μg of vitamin K1, about 5 μg of vitamin K2, about 300 μg of biotin, about 400 μg of folate, about 30 μg of PABA, about 1 mg of boron, about 200 μg of chromium, about 500 μg of copper, about 150 mg of magnesium, about 5 μg of manganese, about 100 μg of molybdenum, about 135 μg of selenium, about 100 μg of vanadium, about 20 mg of zinc, about 150 μg of iodine, about 1.2 mg of pomegranate extract, about 250 mg of bromelain, and about 250 mg of quercetin. Methods for using the compositions and dosage forms for enhancing recovery after surgery or after an athletic performance are also provided herein. The invention also provides kits comprising a composition or dosage form described herein.
4. Targeted breast cancer therapies
Targeted cancer therapies target specific characteristics of cancer cells, or gene mutations that result in tumor development. Targeted therapies as the name specifies specifically target cancer cells and are less likely to harm normal and healthy cells as compared to chemotherapy.
Title: Stable gene targets in breast cancer and use thereof for optimizing therapy
Assignee: Cytognomix Inc. (London, Ontario, CA)
Publication Date: 18 April 2017
Abstract: A method for determining genes in breast cancer that are stable in copy number, expression and sequence in tumors from nearly all patients. Certain stable genes are targets of standard chemotherapy. The effectiveness of therapies that act upon these targets depends on maintaining the stability and integrity of these genes in tumors. Mutations in these targets result in poor response to therapies that target these gene products. In the instant invention, ordinarily stable gene targets are characterized as either normal or mutant for the purpose of determining whether to include or exclude particular drugs as potential treatments.
Title: ADAM22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
Assignee: Royal College of Surgeons in Ireland (Dublin, IE)
Publication Date: 15 March 2016
Abstract: A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumor sample from the patient for expression of A Disintegrin and Metalloproteinase 22, (ADAM22), wherein expression of ADAM22 correlates with increased potential for metastasis compared with a patient who is ADAM22 negative. The invention also describes an agent for use in the treatment of metastatic breast cancer in a patient, in which the agent is selected from leucine-rich, glioma-inactivated protein 1 (LGI1) protein (SEQ ID NO:1) and an LGI1 peptide mimic capable of mimicking the ADAM22 binding activity of LGI1 by binding to the LGI1 binding domain of ADAM22 (SEQ ID NO: 4) and which is capable of inhibiting migration of endocrine resistant breast cancer cells.
Next-generation vaccine platform
It is expected that the medical industry will be seeing an upgrade to the entire vaccine platform to expedite new vaccines while also creating new ways of delivering vaccines.
Title: Multivalent breast cancer vaccine
Assignee: The Cleveland Clinic Foundation (Cleveland, OH, US)
Publication Date: 3 May 2016
Abstract: Compositions and methods for immunization against human breast cancer are disclosed. In one embodiment the multivalent antigenic composition is provided comprising immunogenic polypeptides selected from the group consisting of human α-lactalbumin, αS1 casein, β-casein and κ-casein.
Title: Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines
Assignee: The Catholic University of America (Washington, DC, US)
Publication Date: 3 May 2016
Abstract: Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1 mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.
6. The emergence of distance health
Physicians are working toward a goal of being able to provide healthcare from the comfort of a patient’s home. This means bringing monitoring devices into the homes and the ability to have a physician tell a patient the type of treatment they need to go through for certain conditions without having to go into the doctor’s office.
Title: System and method for remote tele-health services
Assignee: VIDEOKALL, INC. (Potomac, MD, US)
Publication Date: 8 Dec 2015
Abstract: A tele-health services cabin includes a plurality of vital signs monitoring devices, a cabin management unit, and videoconferencing hardware via which a remote practitioner in a remote medical call center videoconferences with a patient in the cabin to diagnose symptoms of the patient. The cabin management unit includes a processor that controls the cabin, a data input at which patient data is provided from the vital signs monitoring devices, and a transmitter connectable to a communication link for bi-directional communication between the cabin management unit and the medical call center, where the transmitter transmits the patient data to the medical call center. The tele-health services cabin may include a patient chair including a motorized seat back and at least one sensor encapsulated in the seat back. The tele-health services cabin may include a hands-free medical device station. The tele-health services cabin may include an automatic cleaning system.
7. The LDL cholesterol lowering drugs
LDL cholesterol lowering drugs are expected to be disruptors in the next year. The new drugs are expected to lower cholesterol to unprecedented levels.
Title: Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
Assignee: Pivotal Therapeutics Inc. (Woodbridge, Ontario, CA)
Publication Date: 10 Feb 2015
Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
Title: 3,3′-disubstituted indolines as inhibitors of cholesterol ester transfer protein
Abstract: 3,3′-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
8. Hybrid closed-loop insulin delivery system
In 2016, the FDA approved the first hybrid closed-loop insulin delivery system. The system is designed to help manage Type 1 diabetes. It is a fully automated insulin delivery system that connects a continuous glucose monitor with an insulin pump, eliminating the need for people with diabetes having to test and manage their insulin levels themselves.
Title: Method and system for closed-loop control of an artificial pancreas
Assignee: Animas Corporation (West Chester, PA, US)
Publication Date: 24 Oct 2017
Abstract: Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin amount for the pump to supply is determined using the temporary insulin delivery profile. Outside that time range, the insulin amount is determined using the base insulin delivery profile. The temporary insulin delivery profile can specify an exact amount to be supplied (a “hard” profile), a nominal amount to be supplied if doing so does not drive glucose out of a desired zone (“soft”), or a soft profile with a minimum amount of insulin to be delivered (“semi-soft”).
Prevnar 13®”- Pfizer’s pneumococcal conjugate vaccine (PCV) Patent in India Case Study
Pneumonia is an acute respiratory infection which affects the lungs. It causes difficulty in breathing and limits oxygen intake. It can be caused by bacteria, fungi or viruses and is a contagious disease. Symptoms of pneumonia include cough, difficulty in breathing, fast breathing or wheezing. Infants may experience an inability to feed or drink, unconsciousness or convulsions, or worse. It is the biggest cause of death among infants in India due to infectious diseases accounting for nearly 20% of global infant pneumonia deaths.
“All our dreams can come true if we have the courage to pursue them.”- Walt Disney
PFIZER is viewed as one of the “World’s biggest pharmaceutical companies”. The company creates and delivers medicines and vaccines for a wide range of restorative orders, including immunology, oncology, cardiology, endocrinology, and neurology.
Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections, cancer, arthritis, and osteoporosis.
“Opportunities don’t happen. You create them.” – Chris Grosser
Indian Patent Office has granted Pfizer Inc. a patent for its powerful pneumonia vaccine“Prevnar 13® ” barring other companies from making affordable copies of the vaccine, giving Pfizer the exclusive right to sell it in India until 2026.
Prevnar 13® is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
“There is no easy walk to freedom anywhere, and many of us will have to pass through the valley of the shadow of death again and again before we reach the mountaintop of our desires.” – Nelson Mandela
The grant of patent to Pfizer Inc.’s pneumonia vaccine, Prevnar 13® was opposed by Indian vaccine maker Panacea Biotec Ltd and MSF (Médecins Sans Frontières) India stating that this would make this vaccine out of reach of thousands in poor nations as several poor nations depend on India’s strong drug industry to supply cheaper copies of medicines and vaccines. The grant of patent for the pneumococcal conjugate vaccine (PCV)- Prevnar 13® means Indian companies won’t be able to make the vaccine for in-house use, or exports.
“If you’re not stubborn, you’ll give up on experiments too soon. And if you’re not flexible, you’ll pound your head against the wall and you won’t see a different solution to a problem you’re trying to solve.” – Jeff Bezos
Panacea Biotec Ltd has filed a review petition with the Controller of Patents seeking the cancellation of the decision of the patent. According to Panacea Biotec, Pfizer’s vaccine does not qualify as an invention as defined under the Indian Patents Act, 1970, and is, therefore, non patentable. Panacea Biotec is developing its own more affordable version of the pneumococcal conjugate vaccine (PCV). It is currently undergoing clinical trials.
“Happiness is a butterfly, which when pursued, is always beyond your grasp, but which, if you will sit down quietly, may alight upon you.” – Nathaniel Hawthorne
MSF(Médecins Sans Frontières)India approached the Delhi high court to revoke the patent. Leena Menghaney, the petitioner who is representing MSF (Médecins Sans Frontières) India said “A public health perspective used for scrutinizing pharmaceutical patent applications is an essential bulwark to ensure wider access to essential medicines and vaccines. Examiners in the Indian patent office must be aware that the decision they take to grant a patent can directly affect access to life-saving medicines and vaccines in India and across the developing world”.
Tech Corp International Strategist (TCIS, India)
Every business has a #strategy. We at TCIS facilitate the process of identifying Key issues and help amplify business goals of any business (short term goals and long term goals). Everything is simple we tend to complicate and use heavy words to prove our point.
In European market Poly Medicure wins patent battle against Braun Melsungen
The patent dispute between the two companies began at the Medica 2009 trade fair
B Braun melsungen (German pharmaceutical) entity is a well known brand in medical technology domain in Europe. However, recently B Braun melsungen has lost a patent dispute with the Indian competitor Polymedicure.
The research and development vertical of Polymedicure is approved by Ministry of Science & Technology Government of India to design & develop new and innovative products from Design to production in a short span of time using rapid prototyping 3 D printer CAD/CAM technology etc. The Indian entity possess ultra modern tool room with sophisticated machines like CNC wire cut, EDM and Vertical Machining Center.
B. Braun is pioneer in research and development of intravenous safety catheters with protection in numerous European countries.
When a physician applies such a catheter to a patient, a needle guard automatically protrudes over the tip when the needle is withdrawn from the arm. This protects the doctor and nursing staff.
It is a known fact that conventional catheters lack such a needle guard. Nurses and other healthcare personnel are routinely injured by the exposed, sharp lancet of the needle after use on a patient. The critical time where a percutaneous injury can occur is from the moment the needle is withdrawn from the patient, or I.V. port, to the time the contaminated needle is safety discarded.
Polymedicure had a similar technology for needle protection and sells intravenous safety catheters which is different from B. Braun patent.
European patent office (EPO) has rejected three B. Braun patents. The patent battle lasted for eight years between B. Braun and Polymedicure.
The New Medical Devices Rules In Drugs And Cosmetics Act, 1940
The Ministry of Health and Family Welfare has published in India’s Official Gazette on October 17, 2016, the new Medical Devices Rules in Drugs And Cosmetics Act, 1940.
The New Medical Devices rules are applicable in respect of –
1). Substances covered under sub-clause (i) of clause (b) of section 3 used for in vitro diagnosis;
2). Substances that are in the nature of mechanical devices covered under sub-clause(ii) of clause (b) of section 3;
3). Devices specified from time to time by the Central Government by notification in the Official Gazette under sub-clause (iv) of clause (b) of section 3 of the Drugs and Cosmetics Act, 1940.
The rules focus on creating a separate registration and oversight system for medical devices and drugs. Also, theses rules define the duties and functions of the Centre Licensing Authority and State Licensing Authority.
Under the new rules-C
The medical devices manufacturers will not have to issue a separate license from the state licensing authority for the manufacturing of Class A and Class B medical devices.
The State Drug Controller is the State Licensing Authority and is the competent authority for enforcement of these rules in matters related to manufacture of Class A and Class B medical Devices.
People engaged in the manufacturing of predicate medical devices will require a separate approval from Centre Licensing Authority before applying to the State Licensing Authority.
According to these new rules medical devices are classified into 4 new classes on the basis of their functions and impact-
The medical devices which will have low risk will fall under Class A;
The medical devices having low moderate risk will fall under Class B;
The medical devices having moderate high risk will fall under Class C
And the medical devices having high risk will fall under Class D.
Every business has a #strategy. #biotech #biopharma #company #startup #makeIndiagreatIndia #research #entrepreneurship #biocurious #medicaldevices #law
Pharmaceutical based Inventions Filed before the Indian Patent Office
The patent examination guidelines for pharmaceutical based inventions cover the following points:
1. Patent Claims Of Pharmaceutical Inventions which includes Markush claims
2. Comprehensive patent search strategy for conducting prior art search by the Patent Examiner
3. Definition of “invention” under section 2(1)(j) of the Indian Patent Act
4. Assessment of Novelty aspect of the invention
5. Assessment of Inventive Step
6. Industrial applicability of the technology
7. Subject matter of Inventions which are not patentable
8. Sufficiency of description, clarity and support of the patent claims in the specification
9. Unity of invention
Patent Search Strategy for Pharmaceutical Inventions:
Comprehensive patent search strategy will be followed by the Indian Patent examiners. The patent search strings will include a combination of various search parameters.
The search parameters will be a combination of keywords, International Patent Classification (IPC), and compound searches. Thorough prior art search is expected to be carried out in patent as well as non-patent databases.
Pharmaceutical Compounds can be searched and identified from the various databases:
a) Molecular formula and structural formula searching;
b) Name searching using IUPAC nomenclature;
c) Compound searching using CAS Registry Numbers;
d) Generic name searching (INN); and
e) Search using International Patent Classification (IPC)
Many a times pharmaceutical compounds which are derivatives of known compounds having established pharmaceutical activities are claimed in the patent specification in the form of generic names (International Non-Proprietary Names, INN). In such cases, the patent examiner will search the prior art with INNs prior art search string. Moreover, in numerous pharmaceutical based inventions the patent applicant claims the second use or an indication in the form of a product claim of an already known pharmaceutical compound or a new form of a known pharmaceutical compound.
Even though, the patent examiner can seek information about the INN of the said pharmaceutical substance claimed in the patent application from the patent applicant there are chances that the conclusions drawn from the information provided may mislead the patent examiner. In my view, the Indian patent examiner can find out more information about the International Non-Proprietary Names by analysing data from the Electronic Orange Book.
Prior Art Search Strategy for Conducting Drug Patent Search in India
Search on Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Search String based on
Therefore, prior art patentability search for patents covering (International Non proprietary Names – INN) as listed in the USFDA Electronic Orange Book should be taken into consideration. However, the Orange Book only provides US patent data. The patentability search can be extended and this information can be further used to conduct patent family searches on EPO website. Further, patentability search can be performed by analysing forward citation and backward citation of the identified patent specifications.
Biological Material and Micro-organism Deposit Details to be Disclosed in the Indian Patent Application
If the invention relates to a biological material which is not possible to be described in a sufficient manner and which is not available to the public, the application shall be completed by depositing the material to an International Depository Authority (IDA) under the Budapest Treaty. The deposit of the material shall be made not later than the date of filing of the application in India and a reference of the deposit shall be given in the specification within three months from the date of filing of the patent application in India. All the available characteristics of the material required for it to be correctly identified or indicated are to be included in the specification including the name, address of the depository institute and the date and number of the deposit.
Every business has a #strategy. We at TCIS,India facilitate the process of identifying Key issues and help amplify business goals of any business (short term goals and long term goals). Everything is simple we tend to complicate and use heavy words to prove our point. We at TCIS believe in BASICs.